On Good Friday, the New York Stock Exchange and Capital Group’s U.S. offices will be closed.

In observance of Good Friday, the New York Stock Exchange and Capital Group’s U.S. offices will be closed on Friday, April 3.

A disciplined approach to growth investing

A flexible approach to global growth investing

An era of innovation

AMCAP strategy

INCEPTION DATE
May 1, 1967

IMPLEMENTATION
Consider for a large-cap growth allocation

OBJECTIVE
Seeks to provide long-term growth of capital 

VEHICLES

AMCAP Fund®

LEARN MORE

Capital Group U.S. Growth SMA

LEARN MORE

A TIME-TESTED PROCESS

For almost 60 years, AMCAP strategy has taken a disciplined approach to growth investing, focusing primarily on well-managed U.S. companies of any size with sound fundamentals, solid long-term growth records and attractive future growth potential.

AN ERA OF INNOVATION

Cutting-edge developments

We may be entering a “golden age” of health care innovation with new treatments emerging that potentially have wide ranging impacts for millions or even billions of people.

Innovation could lead to a golden age in health care

Global revenue from gene therapy and other regenerative medicine (USD billions)

"Global revenue from gene therapy and other regenerative medicine (USD billions). A series of bar charts representing estimates for global revenue from gene therapy and other regenerative medicine. 2022 shows the actual recorded figure for the year, while 2023 through 2032 are estimates: $35 billion in 2022. And an estimated $41 billion in 2023, $48 billion in 2024, $60 billion in 2025, $73 billion in 2026, $86 billion in 2027, $96 billion in 2028, $115 billion in 2029, $134 billion in 2030, $160 billion in 2031 and $195 billion in 2032."

Well-capitalized companies could fund their own growth

Combined cash and short-term investments across MSCI World Pharmaceuticals Index (USD billions)

"Combined cash and short-term investments across MSCI World Pharmaceuticals Index (USD billions). A series of bar charts in the shape of test tubes representing cash and short-term investments across MSCI World Pharmaceuticals Index: $159.2 billion in 2019, $193.9 billion in 2020, $196.1 billion in 2021, $201.3 billion in 2022,$183.6 billion in 2023 and $161 billion in 2024."

One investment strategy, multiple ways to invest

The first is AMCAP Fund, which is offered in various share classes designed for retirement plans, nonprofits, and other institutional and individual investors.

LEARN MORE

For high net worth clients, consider the Capital Group U.S. Growth SMA, which has the same objective and is managed by the same team of portfolio managers.

LEARN MORE
Download Brochure
Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.
Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the mutual fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.
All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies.
Use of this website is intended for U.S. residents only. Use of this website and materials is also subject to approval by your home office.
Advisory services offered through Capital Research and Management Company (CRMC) and its RIA affiliates. Capital Client Group, Inc., member FINRA.
This content, developed by Capital Group, home of American Funds, should not be used as a primary basis for investment decisions and is not intended to serve as impartial investment or fiduciary advice.

Source: MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices.  None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information.  MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information.  Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (msci.com).

The MSCI World Pharmaceuticals, Biotechnology and Life Sciences Index is composed of large and mid cap stocks across 23 Developed Markets countries. All securities in the index are classified in the Pharmaceuticals, Biotechnology and Life Sciences industry group (within the Health Care sector) according to the Global Industry Classification Standard (GICS®).